CollPlant Biotechnologies Ltd.

AI-generated fair value estimate for this company.

Method: Sum-of-parts net-cash-plus-risk-adjusted-pipeline approach: $1.61M net cash ($0.85/share on 1.89M shares) plus ~$11.6M risk-adjusted pipeline/partnership NPV, built from 2x TTM revenue (~$0.64M) for existing bioink/licensing revenue, an 8%-probability-weighted NPV (~$6M of an estimated $80M unadjusted NPV) for the AbbVie/Allergan Aesthetics rhCollagen dermal-filler program, a 5%-probability-weighted NPV (~$3M of an estimated $60M unadjusted NPV) for the regenerative breast-implant program, and a nominal $2M option value for the newly acquired LightSolver photonic-computing business; a 30% going-concern/dilution discount is then applied given under two quarters of cash runway at the current ~$11-13M/yr burn, for ~$9.3M total equity value over 1.89M shares.

Reasoning: CollPlant's trailing revenue ($0.3M-$2.4M) is too small and volatile for a standard revenue-growth DCF, it just executed a 1-for-10 reverse split and faces severe near-term liquidity risk, and it just pivoted into unrelated photonic computing via the LightSolver acquisition, so a heavily risk-adjusted sum-of-parts (net cash plus discounted NPVs for its real but early-stage partnership programs, with a going-concern haircut) is more honest than assuming a stable growth path.